| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/26/2005 | WO2003055475A8 Controlled release pharmaceutical formulation containing venlafaxine |
| 05/26/2005 | US20050113806 Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues |
| 05/26/2005 | US20050113746 System for orally administering active substances, vitamins and/or foodstuffs |
| 05/26/2005 | US20050113745 Programmable implantable pump with accessory reservoirs and multiple independent lumen catheter |
| 05/26/2005 | US20050113579 Antitumor agents; formed by refluxing mixture of amonafide with acetic acid |
| 05/26/2005 | US20050113531 Thermosensitive biodegradable copolymer |
| 05/26/2005 | US20050113418 Improving the inhibition of gastric acid secretion in the treatment of a gastrointestinal disorder by the oral administration of a an acid labile H+, K+-ATPase inhibitor by administering two or more consecutive oral unit dose with 0.5-4 hour intervals; antisecretory, antiulcer agents, e.g., omeprazole |
| 05/26/2005 | US20050113394 Abacavir or salts thereof and a highly compressible carrier such as microcrystalline cellulose; dosage forms; treating HIV; high drug loading tablets of acceptable size for patient compliance |
| 05/26/2005 | US20050113368 eg (+-) Ethyl 3-[4-{3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propylamino}phenyl]-2-ethoxypropanoate; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic |
| 05/26/2005 | US20050113353 Applying gel containing testosterone |
| 05/26/2005 | US20050113337 Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin |
| 05/26/2005 | US20050113317 Such as cromolyn sodium or nedocromil sodium; low amounts of active agents, less prone to detrimental side effects |
| 05/26/2005 | US20050113316 Process for producing dammarane sapogenins and ginsenosides |
| 05/26/2005 | US20050113276 Skin cleaning compounds, body splash, surgical scrub, wound care agents, hand sanitizers, disinfectants, mouthwashes, pet shampoos, hard surface sanitizer; reduction of bacteria, rotavirus, or rhinovirus on skin surface; topical |
| 05/26/2005 | US20050112578 Hybridization of oligonucleotides; three-dimensional; receptivity terminals |
| 05/26/2005 | US20050112325 Drug delivery in association with medical or surgical procedures |
| 05/26/2005 | US20050112235 Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
| 05/26/2005 | US20050112208 Composition for the treatment of burns, sunburns, abrasions, ulcers and cutaneous irritation |
| 05/26/2005 | US20050112207 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
| 05/26/2005 | US20050112205 Method of encapsulating an active substance |
| 05/26/2005 | US20050112204 micellar poloxamer preparation comprising voriconazole and a single poloxamer; increases solubility and aqueous stability |
| 05/26/2005 | US20050112202 tableting processes and equipment, and improved solid dosage forms for oral delivery of drugs that cause contact irritation or ulceration to the lining of the esophagus and stomach |
| 05/26/2005 | US20050112201 Delayed release dosage forms |
| 05/26/2005 | US20050112200 improved absorption, bioavailabilty and/or half-life ; treatment or prevention of atherosclerosis or for the treatment of heavy metal accumulation |
| 05/26/2005 | US20050112199 Therapeutic regimens for administering drug combinations |
| 05/26/2005 | US20050112198 Bupropion formulation for sustained delivery |
| 05/26/2005 | US20050112197 Celecoxib dissolving in polyethylene glycol; antiinflammatory agents, osteoporosis, respiratory system disorders, antitumor agents, analgesics |
| 05/26/2005 | US20050112196 Of water insoluble or poorly soluble neurological agent such as antipsychotic agent or antidepressant e.g. olanzapine, mirtazepine, or risperidone that dissolves in the buccal cavity and has a total weight of less than 500 milligrams |
| 05/26/2005 | US20050112195 Dosage form comprising core of first drug and a coating of a second insoluble drug, hydroxypropyl cellulose, and a water soluble film former of hydroxypropyl methylcellulose, copovidone, and/or a film-forming agent that forms a solid solution with the second drug; organic solvent-free coating |
| 05/26/2005 | US20050112194 Blister packs wherein a portion of the dosage forms are iron-containing and at least half are essentially iron-free; prenatal or postpartum supplements; less chance of accidental iron poisoning of child; iron and calcium can be administered separately for best absorption |
| 05/26/2005 | US20050112193 Immediate-release formulations of acid-labile pharmaceutical compositions |
| 05/26/2005 | US20050112192 Process for preparing formulations of lipid-regulating drugs |
| 05/26/2005 | US20050112191 Novel formulations comprising lipid-regulating agents |
| 05/26/2005 | US20050112190 Dosage form for controlled release of an active agent formulation |
| 05/26/2005 | US20050112189 Hard capsules |
| 05/26/2005 | US20050112186 Nontoxic, biocompatible water in oil emulsion with organic phase of ethenically unsaturated monomers or oligomers that does not provoke an autoimmune or inflammatory response for reforming damaged or diseased intervertebral discs by noninvasive means |
| 05/26/2005 | US20050112185 Positively charged lipid and liposome with the lipid |
| 05/26/2005 | US20050112184 Controlled vesicle self-assembly in continuous two phase flow microfluidic channels |
| 05/26/2005 | US20050112183 with transdermal anesthetic such as lidocaine patch at or near the locus of the negative sensory phenomena |
| 05/26/2005 | US20050112181 By transdermal administration of testosterone in a hydroalcoholic gel; unique pharmacokinetic steady-state profile |
| 05/26/2005 | US20050112177 Gelled composition of whey protein and other beneficial constituents; shelf life; easy to use form |
| 05/26/2005 | US20050112176 Forming a gelled whey protein by processing a mixture of whey protein and other selected ingredients at an appropriate temperature and pH; bioavailable; packaged and easy to store and transport; shelf life |
| 05/26/2005 | US20050112175 Drug delivery device |
| 05/26/2005 | US20050112151 Skin adherent hydrogels |
| 05/26/2005 | US20050112149 Single-dose taste inhibitor units |
| 05/26/2005 | US20050112148 Habit based self-help method for smoking cessation |
| 05/26/2005 | US20050112143 Method of developing an immunogenic composition and HIV vaccine |
| 05/26/2005 | US20050112140 Immunogenic composition and method of developing a vaccine based on portions of the HIV matrix protein |
| 05/26/2005 | US20050112139 Immunogenic composition and method of developing a vaccine based on factor H binding sites |
| 05/26/2005 | US20050112133 Chimera molecule containing protein and merozonite surface protein; induce immunologyresponse against antigens |
| 05/26/2005 | US20050112115 Measurement surface roughtness; calibration of dosage forms |
| 05/26/2005 | US20050112092 Stable, aerosolizable suspensions of proteins in ethanol |
| 05/26/2005 | US20050112087 Pharmaceutical formulations for sustained drug delivery |
| 05/26/2005 | US20050112069 Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist |
| 05/26/2005 | US20050112068 Systems and methods for reducing unintended use of active ingredients in dermal delivery devices |
| 05/26/2005 | US20050109858 Administration form for oral administration of active ingredients, vitamins and/or nutrients |
| 05/26/2005 | CA2805859A1 Il-18 binding proteins |
| 05/26/2005 | CA2549737A1 Polysaccharide-containing composition and tear film stabilizing ophthalmic solution |
| 05/26/2005 | CA2546115A1 Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives |
| 05/26/2005 | CA2545752A1 Treatment and prevention of liver disease associated with parenteral nutrition (pn) |
| 05/26/2005 | CA2545677A1 Method for drug loading in liposomes |
| 05/26/2005 | CA2545458A1 Dry recombinant human alpha 1-antitrypsin formulation |
| 05/26/2005 | CA2545443A1 Solid amorphous dispersions of an mtp inhibitor for treatment of obesity |
| 05/26/2005 | CA2545194A1 Pharmaceutical compositions including low dosages of desmopressin |
| 05/26/2005 | CA2545027A1 Modular imbibition rate reducer for use with implantable osmotic pump |
| 05/26/2005 | CA2544814A1 Non-symmetrical gelling agent |
| 05/26/2005 | CA2544497A1 Multilayer pharmaceutical form comprising a substance having a modular effect in relation to active ingredient release |
| 05/26/2005 | CA2544487A1 Multilayer pharmaceutical form with a matrix which influences the delivery of a modulatory substance |
| 05/26/2005 | CA2544413A1 Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative |
| 05/26/2005 | CA2543815A1 Multi-site drug delivery platform |
| 05/26/2005 | CA2542450A1 Dry powder formulations |
| 05/26/2005 | CA2541944A1 Microparticles comprising somatostatin analogues |
| 05/26/2005 | CA2540383A1 Method for preparing submicron particles of paclitaxel |
| 05/26/2005 | CA2536040A1 Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms |
| 05/25/2005 | EP1532986A2 Pharmaceutical composition for treatment of rhinitis |
| 05/25/2005 | EP1532985A1 Process for producing sustained-release composition |
| 05/25/2005 | EP1532981A1 Stable eye drops containing latanoprost as the active ingredient |
| 05/25/2005 | EP1532975A1 Process for the manufacture of free-flowing, powdery atorvastatin adsorbates |
| 05/25/2005 | EP1532974A2 Aqueous gel comprising 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
| 05/25/2005 | EP1532973A2 Water-soluble film for oral use |
| 05/25/2005 | EP1532149A2 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments |
| 05/25/2005 | EP1532104A1 Crystalline beta-2 adrenergic receptor agonist |
| 05/25/2005 | EP1532102A1 Cosmetic or dermopharmaceutical compositions comprising tyramine derivatives, method for preparing same, and use thereof |
| 05/25/2005 | EP1531888A1 Infusion pump, method, control program and semiconductor means for the dosed administration of a medicinal liquid |
| 05/25/2005 | EP1531879A1 Use of organic compounds |
| 05/25/2005 | EP1531875A1 Active agent delivery system including a poly(ethylene-co-(meth)acrylate), medical device, and method |
| 05/25/2005 | EP1531874A1 Embolization |
| 05/25/2005 | EP1531873A2 Agent delivery particle |
| 05/25/2005 | EP1531868A2 Therapeutic agent-containing polymeric nanoarticles |
| 05/25/2005 | EP1531867A1 Metastable pharmaceutical compositions |
| 05/25/2005 | EP1531866A1 Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| 05/25/2005 | EP1531862A1 Stabilized liquid anti-rsv antibody formulations |
| 05/25/2005 | EP1531856A1 Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases |
| 05/25/2005 | EP1531851A2 Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use |
| 05/25/2005 | EP1531847A2 Pharmaceutical formulation |
| 05/25/2005 | EP1531837A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| 05/25/2005 | EP1531835A2 Micelle assemblies |
| 05/25/2005 | EP1531831A1 Fosinopril formulation |
| 05/25/2005 | EP1531814A1 Sustained-release tablet composition of pramipexole |
| 05/25/2005 | EP1531805A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |